Project BioShield Annual Report to Congress: August 2006 through July 2007 Released During the current reporting period, HHS engaged in substantial BioShield-enabled acquisition activities (a) to award a contract for acquisition of Modified Vaccinia Ankara (MVA) smallpox vaccine, (b) to initiate a sole-source acquisition of additional Anthrax Vaccine Adsorbed (AVA); and (c) to pursue acquisition both of recombinant protective antigen (rPA) vaccine for anthrax, and of therapeutics to mitigate or treat neutropenia associated with acute radiation syndrome (ARS). Learn More >> Medical Planning and Countermeasures Learn More >> | In The Spotlight Operations and Training Learn More >> Communicating in a Crisis Learn More >> News In Pictures
Learn More >> |